He J, Kam YW. Insights from avian influenza: A review of its multifaceted nature and future pandemic preparedness. Viruses 2024; 16(3): 458. [http://dx.doi.org/10.3390/v16030458] [PMID: 38543823]
[23]
Zheng S, Tang L, Gao H, et al. Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A (H7N9) virus. Clin Infect Dis 2018; 66(7): 1054-60. [http://dx.doi.org/10.1093/cid/cix930] [PMID: 29077848]
[24]
Li Y, Huo S, Yin Z, et al. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. MBio 2023; 14(5): e01273-23. [http://dx.doi.org/10.1128/mbio.01273-23] [PMID: 37610204]
Pitisuttithum P, Boonnak K, Chamnanchanunt S, et al. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2017; 17(8): 833-42. [http://dx.doi.org/10.1016/S1473-3099(17)30240-2] [PMID: 28533093]
[27]
Maartens LH, Frizzo da Silva L, Dawson S, Love N, Erasmus BJ. The efficacy of an inactivated avian influenza H5N1 vaccine against an African strain of HPAI H5N8 (clade 2.3.4.4 B). Avian Pathol 2023; 52(3): 176-84. [http://dx.doi.org/10.1080/03079457.2023.2181145] [PMID: 37079321]
[28]
Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011; 203(5): 666-73. [http://dx.doi.org/10.1093/infdis/jiq093] [PMID: 21282194]
[29]
Islam MS, Miah M, Hossain ME, Kibria KK. A conserved multi-epitope-based vaccine designed by targeting hemagglutinin protein of highly pathogenic avian H5 influenza viruses. 3 Biotech 2020; 10: 1.: 6.
[30]
Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 2019; 37(25): 3326-34. [http://dx.doi.org/10.1016/j.vaccine.2019.04.074] [PMID: 31079849]